Imunon, Inc. (IMNN) chair receives 4,603-share stock salary grant

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. executive chairman Michael H. Tardugno received a grant of 4,603 shares of common stock on July 17, 2026 at $1.83 per share, issued in lieu of cash base salary. Following this award he directly holds 68,999 shares, plus 4,622 shares held indirectly through an IRA.

Insider Trade Summary

Net Buyer: 4,603 shares

Net Buy 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	4,603	$1.83	$8K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 68,999 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Stock grant shares: 4,603 shares Grant price per share: $1.83 per share Direct holdings after grant: 68,999 shares +1 more

4 metrics

Stock grant shares 4,603 shares Common stock granted on July 17, 2026 in lieu of base salary

Grant price per share $1.83 per share Valuation used for the July 17, 2026 stock grant

Direct holdings after grant 68,999 shares Direct Imunon common stock held by Tardugno following the reported grant

Indirect IRA holdings 4,622 shares Imunon common stock reported as indirectly held, nature of ownership “Held by IRA”

Key Terms

Grant, award, or other acquisition, Held by IRA, indirect ownership

3 terms

Grant, award, or other acquisition regulatory

"transaction code description notes a “Grant, award, or other acquisition” of shares"

Held by IRA financial

"nature_of_ownership for one line is described as “Held by IRA” for 4,622 shares"

indirect ownership financial

"ownership_type is indirect for shares noted as “Held by IRA”, indicating indirect ownership"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 04:17 PM Accepted by SEC EDGAR 07/21/2026 - 04:17 PM Learn about SEC filing dates

FAQ

What stock grant did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported that executive chairman Michael H. Tardugno received a grant of 4,603 common shares on July 17, 2026 at $1.83 per share. The grant was described as stock issued in lieu of cash for his base salary.

Was Michael H. Tardugno’s Imunon (IMNN) transaction a market purchase?

No. The Form 4 describes the Imunon shares as a grant, award, or other acquisition, with a footnote stating they were stock granted in lieu of cash for base salary. This indicates a compensation-related award, not an open-market purchase.

How many Imunon (IMNN) shares does Tardugno hold after the reported grant?

After the July 17, 2026 grant, Michael H. Tardugno directly holds 68,999 Imunon common shares. A separate line on the Form 4 also shows 4,622 additional shares reported as indirectly held through an IRA account.

How are some of Michael H. Tardugno’s Imunon (IMNN) shares held?

In addition to his direct holdings, the filing lists 4,622 Imunon shares as indirectly held with the ownership nature described as “Held by IRA”. This indicates those shares are in an IRA associated with him.

Were Tardugno’s Imunon (IMNN) transactions under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, meaning the reported grant was not designated as made under a pre-arranged 10b5-1 trading plan based on the form’s plan-status field.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2026		A		4,603(1)	A	$1.83	68,999	D
Common Stock								4,622	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)